

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)

No. BPPI/Drug- 044/2016

Dated: 13/08/2019

Order

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs- 044/2016 dated 28.10.2016 through e-procurement system i,e CPP Portal for supply of drugs for the year 2016-2017.

Whereas, M/s Max Chem Pharmaceuticals Pvt Limited Plot No. 22, Sec-3, Sidcul-IIE, Rudrapur, Distt. US Nagar (Uttarakhand) 263153 had participated in the tender. The firm was awarded Drug code 289 Losartan Potassium 50mg Tablets and Drug code 145 Metformin tablets 500 mg supply to BPPI, New Delhi for the period of 2 years as per tender provision. Samples of Drug code 289 Losartan Potassium 50mg Tablets having batch no. MJ-181 and Drug code 145 Metformin tablets 500 mg Batch no MJ-140 were found NOT OF STANDARD QUALITY after testing in Government laboratory as per details below:

Date of initiation by BPPI	Product Name	Batch No.	Mfg. Date	Exp. Date	Reason of rejection	Failed by	Report no.
07/08/2018	Losartan Potassiu m 50mg Tablets	MJ-181	12/2016	11/2018	Dissolution	Drug inspector, Guntur, State- Andra Pradesh	1310/APDCL/2 018
19/01/2019	Metformi n tablets IP 500 mg	MJ-140	12/2016	11/2018	Uniformity of weight of tablets	Drug Inspector Mangalore	MN2/TEST/71/ 2017-18

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice on dt 13/08/2018 to the firm informing about provisions of the clause no. 15.2, 19.2 & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken:-

(ii) blacklisting/debarring of the firm as per clause 19.2 and 20.1(a) of tender document.

Whereas, the firm vide their letter dated 19/01/2019 informed that they have challenged the NSQ drug to CDL, but BPPI not received any letter/test report from any drug department and CDL. The Explanation of the firm is not acceptable as the reports received from the Government Drug Testing Laboratory will be conclusive, final and binding on the suppliers in terms of provision of clause 20.2.1 (f) of tender document.

In view of above, the firm is debarred for a period of 2 years to participate in any tender of BPPI for supplying of drug i.e. Drug code 289 Losartan Potassium 50mg Tablets and Drug code 145 Metformin tablets 500 mg from date of issuance of this order.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau of Pharma Public Sector Undertakings of India, New Delhi in the matter.

Sachin Singh, IRS Chief Executive Officer For & on Behalf of BPPI, New Delhi

To

M/s Max Chem Pharmaceuticals Pvt Limited Plot No. 22, Sec-3, Sidcul-IIE, Rudrapur, Distt. US Nagar (Uttarakhand) 263153

Page 1 of 1

Videocon Tower, 8th Floor, E-1, Jhandewalan Extension, New Delhi-110055 Tel.: 011-49431800, Tollfree No.: 18001808080, Website: janaushadhi.gov.in